C9orf72 and frontotemporal dementia: In this cohort the assay had 100% sensitivity and 100% specificity and showed an eightfold difference in signal between controls and the patient with C9FTD with the lowest poly(GP) levels, indicating that it can be used as a target engagement biomarker for C9orf72 FTD/ALS.